DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
01 2022
Historique:
received: 27 05 2021
revised: 18 08 2021
accepted: 21 10 2021
pubmed: 27 10 2021
medline: 12 3 2022
entrez: 26 10 2021
Statut: ppublish

Résumé

Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer histotype that tends to be resistant to standard platinum-based chemotherapeutics. We sought to better understand the role of DNA methylation in clinical and biological subclassification of OCCC. We interrogated genome-wide methylation using DNA from fresh frozen tumors from 271 cases, applied nonsmooth nonnegative matrix factorization (nsNMF) clustering, and evaluated clinical associations and biological pathways. Two approximately equally sized clusters that associated with several clinical features were identified. Compared with Cluster 2 ( DNA methylation clusters in OCCC correlate with disease features and gene expression patterns among immune pathways. This work serves as a foundation for integrative analyses that better understand the complex biology of OCCC in an effort to improve potential for development of targeted therapeutics.

Sections du résumé

BACKGROUND
Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer histotype that tends to be resistant to standard platinum-based chemotherapeutics. We sought to better understand the role of DNA methylation in clinical and biological subclassification of OCCC.
METHODS
We interrogated genome-wide methylation using DNA from fresh frozen tumors from 271 cases, applied nonsmooth nonnegative matrix factorization (nsNMF) clustering, and evaluated clinical associations and biological pathways.
RESULTS
Two approximately equally sized clusters that associated with several clinical features were identified. Compared with Cluster 2 (
CONCLUSIONS
DNA methylation clusters in OCCC correlate with disease features and gene expression patterns among immune pathways.
IMPACT
This work serves as a foundation for integrative analyses that better understand the complex biology of OCCC in an effort to improve potential for development of targeted therapeutics.

Identifiants

pubmed: 34697060
pii: 1055-9965.EPI-21-0677
doi: 10.1158/1055-9965.EPI-21-0677
pmc: PMC8755592
mid: NIHMS1752802
doi:

Substances chimiques

ARID1A protein, human 0
DNA-Binding Proteins 0
TP53 protein, human 0
Transcription Factors 0
Tumor Suppressor Protein p53 0
Class I Phosphatidylinositol 3-Kinases EC 2.7.1.137
PIK3CA protein, human EC 2.7.1.137

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

132-141

Subventions

Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA228991
Pays : United States
Organisme : Cancer Research UK
ID : 15601
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA248288
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA222867
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA136393
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
BMC Cancer. 2018 Mar 27;18(1):347
pubmed: 29587661
Gynecol Oncol. 2012 Sep;126(3):481-90
pubmed: 22525820
Ann Oncol. 2013 Dec;24 Suppl 10:x16-21
pubmed: 24265397
J Clin Invest. 2020 May 1;130(5):2712-2726
pubmed: 32027624
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Nat Genet. 2019 May;51(5):815-823
pubmed: 31043753
Biopreserv Biobank. 2013 Apr;11(2):83-93
pubmed: 24845429
Bioinformatics. 2014 Apr 1;30(7):1015-6
pubmed: 24371154
Clin Cancer Res. 2019 Oct 1;25(19):5937-5946
pubmed: 31142506
Gynecol Oncol. 2018 Nov;151(2):381-389
pubmed: 30217369
N Engl J Med. 2010 Oct 14;363(16):1532-43
pubmed: 20942669
Int J Gynecol Cancer. 2021 Apr;31(4):605-616
pubmed: 32948640
J Gynecol Oncol. 2017 Nov;28(6):e77
pubmed: 29027395
Nat Genet. 2017 May;49(5):680-691
pubmed: 28346442
Healthcare (Basel). 2019 Jul 30;7(3):
pubmed: 31366141
EBioMedicine. 2019 Dec;50:203-210
pubmed: 31761620
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4164-9
pubmed: 15016911
Nature. 1999 Oct 21;401(6755):788-91
pubmed: 10548103
Int J Mol Sci. 2013 Mar 06;14(3):5367-79
pubmed: 23466883
Hum Mol Genet. 2015 Jul 1;24(13):3595-607
pubmed: 25804953
Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1677-86
pubmed: 23880734
Nat Commun. 2013;4:1628
pubmed: 23535649
Clin Cancer Res. 2018 Feb 1;24(3):569-580
pubmed: 29061645
Mod Pathol. 2017 Feb;30(2):297-303
pubmed: 27767100
Future Oncol. 2015;11(9):1389-405
pubmed: 25952785
Genome Biol. 2010;11(2):R14
pubmed: 20132535
Sci Rep. 2020 May 14;10(1):7946
pubmed: 32409713
Genome Biol. 2016 Oct 7;17(1):208
pubmed: 27717381
JCI Insight. 2016 Aug 18;1(13):
pubmed: 27617304
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
BJOG. 2020 Oct;127(11):1409-1420
pubmed: 32285600
Clin Cancer Res. 2011 Apr 15;17(8):2538-48
pubmed: 21343371
Hum Mol Genet. 2013 Aug 1;22(15):3038-47
pubmed: 23571109
Science. 2010 Oct 8;330(6001):228-31
pubmed: 20826764
Cancer Discov. 2015 Jul;5(7):752-67
pubmed: 26069190
Am J Surg Pathol. 2020 May;44(5):649-656
pubmed: 32294063
J Pathol. 2015 Jun;236(2):201-9
pubmed: 25692284
Int J Oncol. 2012 Sep;41(3):1094-100
pubmed: 22751940
Int J Gynecol Cancer. 2016 May;26(4):648-54
pubmed: 26937756
IEEE Trans Pattern Anal Mach Intell. 2006 Mar;28(3):403-15
pubmed: 16526426
J Pathol. 2018 Apr;244(5):550-564
pubmed: 29344971
J Gynecol Oncol. 2016 May;27(3):e31
pubmed: 27029752

Auteurs

Julie M Cunningham (JM)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. cunningham.julie@mayo.edu.

Stacey J Winham (SJ)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.

Chen Wang (C)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.

Britta Weiglt (B)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Zhuxuan Fu (Z)

Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.

Sebastian M Armasu (SM)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.

Bryan M McCauley (BM)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.

Alison H Brand (AH)

Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
University of Sydney, Sydney, New South Wales, Australia.

Yoke-Eng Chiew (YE)

Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.

Esther Elishaev (E)

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Charlie Gourley (C)

Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.

Catherine J Kennedy (CJ)

Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.

Angela Laslavic (A)

Womens Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania.

Jenny Lester (J)

David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.

Anna Piskorz (A)

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.

Magdalena Sekowska (M)

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.

James D Brenton (JD)

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.

Michael Churchman (M)

Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.

Anna DeFazio (A)

Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
University of Sydney, Sydney, New South Wales, Australia.
Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.

Ronny Drapkin (R)

Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Kevin M Elias (KM)

Brigham and Women's Hospital, Boston, Massachusetts.

David G Huntsman (DG)

British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.

Beth Y Karlan (BY)

David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.

Martin Köbel (M)

Department of Laboratory and Pathology Medicine, University of Calgary, Calgary, Alberta, Canada.

Jason Konner (J)

Weill Cornell Medical College of Cornell University, New York, New York.
Department of Medicine, Washington University, St. Louis, Missouri.

Kate Lawrenson (K)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Women's Cancer Program at the Samuel Oschin Cancer Institute Cedars-Sinai Medical Center, Los Angeles, California.

Elli Papaemmanuil (E)

Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Kelly L Bolton (KL)

Department of Medicine, Washington University, St. Louis, Missouri.

Francesmary Modugno (F)

Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Womens Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania.
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Ellen L Goode (EL)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH